on INVENTIVA (EPA:IVA)
Inventiva Reports Preliminary 2024 First-Half Financial Information
Inventiva, a clinical-stage biopharmaceutical company, disclosed its preliminary financial results for the first half of 2024. As of June 30, 2024, cash and cash equivalents stood at €10.1 million, a significant decline from €26.9 million at the end of 2023. The company issued royalty certificates worth €20.1 million to investors in July, including Samsara BioCapital and existing shareholders.
No revenues were recorded in H1 2024, contrasting with €1.9 million in the same period of 2023. This decline is attributed to the absence of milestone payments like those received in 2023. R&D expenses decreased by 10% to €48.7 million, largely due to a temporary suspension of patient recruitment in its NATiV3 Phase III trial.
The company faces substantial doubt regarding its ability to continue operations beyond September 2024 without securing additional funds. Inventiva is actively exploring various financing options to support its ongoing and future activities.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INVENTIVA news